The decision on Coherus's request can not take more than 12 months according to the IPR rules. If the decision is unfavorable to Abbvie, Abbvie could appeal the decision and delay competition by up to another 12 months. So, probably no immediate competition to Humira, but something to watch. Today was an excellent day to close out previously sold calls for a nice profit and buy calls at a cheap price. Abbvie is a great trading stock and the dividend, which was received today, is also great. Lots to love about Abbvie.